Spyre Q2 net loss narrows to $38.8M; SPY001 Phase 1 dosed, interim data by year-end

Spyre Therapeutics, Inc.

2024-Q2 EPS reported -$2.02

Net loss narrowed to $38.8M in Q2 2024 from $217.1M in Q2 2023; cash and securities $426.3M.
R&D expenses increased to $32.6M (vs $17.4M) driven by IBD pipeline advancement; no acquired IPR&D in Q2 2024.
SPY001 (anti-α4β7) Phase 1 dosing initiated; interim proof-of-concept data expected by end of 2024 for every-8-12 week dosing.
SPY002 (anti-TL1A) two candidates with subnanomolar potency; FIH trials in H2 2024 with interim data in H1 2025.
SPY003 (anti-IL-23) development candidate nominated; FIH trial expected in H1 2025; $426M cash runway into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.